Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Washington University SPORE in Pancreatic Cancer

Award Number: P50CA272213
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/28/2023
PERIOD OF PERFORMANCE END DATE: 06/30/2028

Group Awards By:

View Award Description

Washington University SPORE in Pancreatic Cancer - The Washington University Specialized Program of Research Excellence (SPORE) in Pancreatic Cancer is a highly translational cancer research program focused entirely on the deadliest form of the disease, pancreatic ductal adenocarcinoma (PDAC). Our outstanding investigators have complementary expertise in basic and clinical studies, and our teams leverage individual expertise in immunology, cancer biology, drug development, genomics, and clinical care to develop novel diagnostic and therapeutic approaches for Pancreatic Ductal Adenocarcinoma (PDAC). This SPORE application includes three research projects, an administrative core (Core A), two shared-resource cores [Biospecimen Core (Core B) and Biostatistics and Bioinformatics Core (Core C)], and developmental research (DRP) and career enhancement (CEP) programs. In collaboration with our External (EAB) and Internal (IAB) Advisory Boards, we intentionally selected projects with the greatest potential to impact the outcome for patients with PDAC. Basic research at WUSM and UPenn has led to the development of the following three research projects, all of which feature innovative investigator-initiated therapeutic trials for PDAC. All projects deemed to have the most potential for translational impact and share an immunologic theme in their approach. This immunologic theme leverages institutional strengths and highlights our team’s expertise and leadership in this field. Thus far, the immunologic and metabolic therapies that have been increasingly successful for controlling other cancer types have not been impactful in PDAC. Our project leaders have made noteworthy contributions to elucidate the mechanisms underlying this immunologic resistance and drug resistance in PDAC and developed several exciting strategies with potential to overcome these obstacles. The three projects in this application are designed to have significant potential to change clinical practice within 5 years. Project 1. Employing CD11b-agonists to render PDAC responsive to immunotherapy Project 2. Mechanisms of Resistance to Neoantigen Vaccines in PDAC Project 3. Targeting Stress-induced MK2 as Novel Strategy in Pancreatic Cancer Our long-term goals are to improve the survival and the quality of life of patients diagnosed with PDAC. To achieve this goal, we will promote institutional and inter-institutional collaborative research, with an emphasis on translation. We anticipate that no singular approach will solve PDAC and fully commit to supporting the development of novel research concepts as well as highly promising young investigators. Our SPORE will provide access to pancreatic cancer–specific resources to facilitate this mission.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Centers Support Grants	000	3	3/12/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $2,178,396 )
2025	2025	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Centers Support Grants	001	3	9/22/2025	NON-COMPETING CONTINUATION	$2,178,396
2025	2024	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Centers Support Grants	000	2	5/26/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,178,396

Issue Date FY: 2024 ( Subtotal = $2,091,214 )
2024	2024	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Cancer Centers Support Grants	002	2	9/5/2024	NON-COMPETING CONTINUATION	$2,091,214
2024	2023	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Cancer Centers Support Grants	000	1	3/21/2024	NEW	$0
2024	2023	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63110	SAINT LOUIS CITY	USA	Cancer Centers Support Grants	001	1	4/1/2024	NEW	$0
														Subtotal = $2,091,214

Issue Date FY: 2023 ( Subtotal = $2,065,042 )
2023	2023	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Centers Support Grants	000	1	8/30/2023	NEW	$2,065,042
														Subtotal = $2,065,042

Grand Total All Awards = $6,334,652

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Washington University SPORE in Pancreatic Cancer

Award Number: P50CA272213

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/28/2023

PERIOD OF PERFORMANCE END DATE: 06/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer